New radioactive drug targets tough prostate cancers
NCT ID NCT05983198
First seen Sep 30, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread. The drug seeks out and delivers radiation to cancer cells. The goal is to find a safe dose and see if it shrinks tumors. About 33 men with either hormone-sensitive or castration-resistant prostate cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Novartis Investigative Site
Darlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Clermont-Ferrand, 63011, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511, France
Conditions
Explore the condition pages connected to this study.